Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current antidementive therapy].

R Perneczky1, A Kurz

  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie der TU München. robert.perneczky@lrz.tu-muenchen.de

MMW Fortschritte Der Medizin
|September 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis.

European journal of nuclear medicine and molecular imaging·2025
Same author

SMAS: Structural MRI-based AD Score using Bayesian supervised VAE.

Computers in biology and medicine·2025
Same author

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.

The journal of prevention of Alzheimer's disease·2024
Same author

Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults.

The journal of prevention of Alzheimer's disease·2024
Same author

Influence of cochlear parameters on the current practice in cochlear implantation : Development of a concept for personalized medicine.

HNO·2021
Same author

[Influence of cochlear parameters on the current practice in cochlear implantation : Development of a concept for personalized medicine. German version].

HNO·2020

Early initiation and adequate duration of antidementia treatments are crucial for managing dementia symptoms. Maximum doses of approved drugs like acetylcholinesterase inhibitors and memantine are recommended for optimal efficacy in Alzheimer

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Context:

  • Dementia management requires timely and effective therapeutic interventions.
  • Current treatments aim to slow cognitive decline and improve patient quality of life.
  • Alzheimer's disease is a progressive neurodegenerative disorder with significant impact.

Purpose:

  • To review the efficacy and application of current antidementia treatments.
  • To provide guidance on optimal dosing and treatment duration for dementia.
  • To highlight approved pharmacological options for different stages of Alzheimer's disease.

Summary:

  • Acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) are approved for mild-to-moderate Alzheimer's dementia.
  • Memantine, an NMDA inhibitor, is indicated for moderate-to-severe Alzheimer's disease.

Related Experiment Videos

  • Ginkgo biloba and piracetam serve as alternative options for specific patient groups.

    • Impact:

    • Early and appropriate use of antidementia drugs can significantly delay symptom progression.
    • Optimizing drug dosage and duration maximizes therapeutic benefits.
    • This evidence-based approach supports improved clinical outcomes in dementia care.